Outcome
Type |
Measure |
Description |
Time frame |
Safety issue |
Other |
Patient satisfaction |
Patients self-report of satisfaction with the GLA:D program. |
Primary follow-up point: Completion of GLA:D program (an average of three months). Secondary follow-up point: 12 months |
|
Other |
Continuation of exercise |
Patients self-reporting if, how and where they have continued exercising. |
Follow-up point: 12 months |
|
Other |
Self-reported activity levels |
Patients self-report their current activity levels using the University of California, Los Angeles (UCLA) activity scale, ranging from 1 (inactive, dependent on others) to 10 (regular participation in high-impact sports). |
Primary follow-up point: Change from baseline to completion of GLA:D program (an average of three months). Secondary follow-up point: 12 months |
|
Other |
Usage of what was learned during GLA:D |
Patients self-report of use of acquired skills and knowledge from the GLA:D program. |
Primary follow-up point: Completion of GLA:D program (an average of three months). Secondary follow-up point: 12 months |
|
Other |
Symptom management |
Patients self-report of how they handle flare-ups in their knee OA symptoms. |
Primary follow-up point: Change from baseline to completion of GLA:D program (an average of three months). Secondary follow-up point: 12 months |
|
Other |
Intake of pain killers |
Intake of painkillers is evaluated by the physiotherapist asking the patients about intake of any joint related medication. If taking painkillers, the patients are asked which type and whether or not they were taken because of their knee pain. |
Primary follow-up: Change from baseline to completion of GLA:D program (an average of three months). |
|
Other |
Sick leave |
Patients self-report of sick leave due to knee symptoms. |
Follow-up points: Baseline and 12 months |
|
Other |
Health-related quality of life, index score |
Patients self-report of their health situation using EuroQol, 5 dimensions, 5 levels (EQ-5D-5L) score (-0.624 to 1; worst to best). |
Primary follow-up point: Change from baseline to completion of GLA:D program (an average of three months). Secondary follow-up point: 12 months |
|
Other |
Health-related quality of life, visual analogue scale |
Patients self-report of their health situation using the EuroQol visual analogue scale (EQ VAS), ranging from 0-100 (worst to best). |
Primary follow-up point: Change from baseline to completion of GLA:D program (an average of three months). Secondary follow-up point: 12 months |
|
Other |
Global perceived effect |
Patients self-report of current knee condition compared to before participation in GLA:D, scored on a 7-point likert scale (much worse to much better). |
Primary follow-up point: Completion of GLA:D program (an average of three months). Secondary follow-up point: 12 months |
|
Other |
Pain during exercise (only for on-line group) |
Patients self-report of pain during each exercise session, rated using a numeric pain rating scale (NPRS) 0-10, with zero representing no pain and 10 representing extreme pain. |
Immediately prior to, and immediately after each exercise session |
|
Primary |
Knee impact summary |
Summary score from the Knee injury and Osteoarthritis Outcome Score, short version (KOOS 12). The summary score is calculated as the average score from the KOOS 12 subscales pain, function and quality of life (QOL), ranging from 0 (worst) to 100 (best). |
Primary follow-up point: Change from baseline to completion of GLA:D program (an average of three months). Secondary follow-up point: 12 months |
|
Secondary |
Fast-paced walking ability |
Fast-paced walking ability is recorded by the physiotherapists and evaluated using the 40-m fast-paced walk test. |
Primary follow-up point: Change from baseline to completion of GLA:D program (an average of three months) |
|
Secondary |
Chair-stand ability |
Chair-stand ability is recorded by the physiotherapists and evaluated using the 30-s chair-stand test. |
Primary follow-up point: Change from baseline to completion of GLA:D program (an average of three months) |
|
Secondary |
Self-reported function |
Patients self-report of function during daily life using the subscale function from the KOOS 12 questionnaire with scores ranging from 0 (worst) to 100 (best). |
Primary follow-up point: Change from baseline to completion of GLA:D program (an average of three months). Secondary follow-up point: 12 months |
|
Secondary |
Self-reported pain |
Patients self-report of pain using the subscale pain from the KOOS 12 questionnaire with scores ranging from 0 (worst) to 100 (best). |
Primary follow-up point: Change from baseline to completion of GLA:D program (an average of three months). Secondary follow-up point: 12 months |
|
Secondary |
Self-reported quality of life |
Patients self-report of quality of life using the subscale quality of life from the KOOS 12 questionnaire with scores ranging from 0 (worst) to 100 (best). |
Primary follow-up point: Change from baseline to completion of GLA:D program (an average of three months). Secondary follow-up point: 12 months |
|
Secondary |
Pain intensity |
Mean pain intensity during the last week in the most affected knee is evaluated on a 100 mm visual analogue scale (VAS) with terminal descriptors of 'no pain' (0 mm) and 'maximum pain' (100 mm). |
Primary follow-up point: Change from baseline to completion of GLA:D program (an average of three months). Secondary follow-up point: 12 months |
|
Secondary |
Physical activity and exercise |
Patients self-report of time spent (frequency and duration) on structured physical activity and exercise. |
Primary follow-up point: Change from baseline to completion of GLA:D program (an average of three months). Secondary follow-up point: 12 months |
|